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Use of medical tests should be guided by research
evidence about the accuracy and utility of those tests
in clinical care settings. Systematic reviews of the
literature about medical tests must address applica-
bility to real-world decision-making. Challenges for
reviews include: (1) lack of clarity in key questions
about the intended applicability of the review, (2)
numerous studies in many populations and settings,
(3) publications that provide too little information to
assess applicability, (4) secular trends in prevalence
and the spectrum of the condition for which the test is
done, and (5) changes in the technology of the test
itself. We describe principles for crafting reviews that
meet these challenges and capture the key elements from
the literature necessary to understand applicability.
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INTRODUCTION
Most systematic reviews are conducted for a practical
purpose: to support clinicians, patients, and policy makers—
decision makers—in making informed decisions. To make
informed decisions about medical tests, whether diagnostic,
prognostic or those used to monitor the course of disease or
treatment, decision makers need to understand whether a test
is worthwhile in a specific context. For example, decision
makers need to understand whether a medical test has been
studied in patients and care settings similar to those in which
they are practicing, and whether the test has been used as part
of the same care management strategy that they plan to use.
They may also want to know whether a test is robust over a
wide range of scenarios for use or relevant only to a narrow
set of circumstances.
Agency for Healthcare Research and Quality (AHRQ)
Evidence-based Practice Centers (EPC) review scientific
literature on topics including clinical care and medical tests
to produce evidence reports and technology assessments to
inform coverage decisions, quality measures, educational
materials and tools, guidelines, and research agendas. The
EPCs use four principles for assessing and reporting
applicability of individual studies and the overall applica-
bility of a body of evidence. These principles may provide
a useful framework for other investigators conducting
systematic review of medical tests:
1
& Determinethemostimportantfactorsthataffectapplicability
& Systematically abstract and report key characteristics that
may affect applicability
& Make and report judgements about major limitations to
applicability of individual studies
& Consider and summarize the applicablity of the body of
evidence
Comprehensive information about the general conduct of
reviews is available in the AHRQ Evidence-based Practice
Center Methods Guide for Comparative Effectiveness
Reviews.
2 In this report we highlight common challenges
in reviews of medical tests and suggest strategies that
enhance interpretation of applicability.
COMMON CHALLENGES
Key Questions Lack Clarity. Key questions guide the
presentation, analysis, and synthesis of data, and thus the
ability to judge applicability. Key questions should provide
a clear context for determining the applicability of a study.
Lack of specificity in key questions can result in reviews of
larger scope than necessary, failure to abstract relevant
study features for evidence tables, less useful organization
of summary tables, disorganized synthesis of results, and
findings from meta-analysis that do not aggregate data in
crucial groupings. In addition, key questions that do not
distinguish the management context in which the test is
being used can introduce misinterpretations of the literature.
A common scenario for such confusion is when the research
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replacement), but in reality, the test is proposed to be used
as a triage test to guide further testing or as an add-on after
another test.
If relevant contextual factors are not stipulated in the key
questions, it also hinders decisions during the review process.
Which studies should be included and which excluded? If the
patient population and care setting are not explicitly
described, the default can be to broadly lump all contexts
and uses of the test together. However, decisions to “lump”
or “split” must be carefully considered and justified.
Inappropriate lumping without careful consideration of
subgroups that should be analyzed separately may result in
oversimplification. Decisions about meaningful subgroupings,
for instance by age of participants, by setting (hopsital versus
ambulatory), or version of the test, should be made in advance.
Conducting subgroup analyses after appraising the
included studies may introduce type 1 error from a
posteriori biases in interpretation, making it difficult to
distinguish whether identified effects are spurious or real.
Decisions in advance to split reporting of results for specific
subgroups and contexts should be carefully considered and
justified. Decisions should be based on whether there is
evidence that a particular contextual factor is expected to
influence the performance characteristics of the test or its
effectiveness as a componenet of care.
Studies Are Not Specific to the Key Questions. When there
is appropriate justification to “split” a review so that key
questions or subquestions relate to a specific population,
setting, or management strategy, the studies identified for
inclusion may not reflect the same subgroups or
comparisons identified in the key questions. The reviewer
is faced with deciding when these deviations from ideal are
minor, and when they are more crucial and are likely to
affect test performance, clinical decision-making, and health
outcomes in some significant way. The conduct and
synthesis of the findings will require a method to track
and describe how the reviewers dealt with two types of
mismatches: (1) literature from other populations and
contexts that does not directly address the intended
context of the key question; and (2) studies that do not
provide sufficient information about context to determine if
they apply. Annotation througout the review, in tables and
synthesis, can then note if these types of mismatch apply,
how common they were, and what the expected impact is
on interpreting applicability.
Tests Are Rapidly Evolving. A third challenge, especially
relevant to medical tests, is that, even more than treatments,
tests often change rapidly, in degree (enhancements in
existing technologies), type (substantively new technologies),
or target (new molecular targets). The literature often contains
evidence about tests that are not yet broadly available or are
no longer common in clinical use. Secular trends in use
patterns and market forces may shape applicability in
unanticipated ways. For instance, suppose that a test is
represented in the literature by dozens of studies that report
on a version that provides dichotomous, qualitative results
(present versus absent), and that the company marketing the
test subsequently announces production of a new version that
provides only a continuous, quantitative measure. Or genetic
tests for traits may evolve from testing for a single-nucleotide
polymorphisms to determining the gene sequence. In these
situations, reviewers must weigh how best to capture data
relating the two versions of the test and decide whether there
is value in reviewing the obsolete test to provide a point of
reference for expectations about whether the replacement test
has any merit or whether reviewing only the more limited,
newer data better addresses the key question for
contemporary practice.
PRINCIPLES FOR ADDRESSING CHALLENGES
The root cause of these challenges is that test accuracy, as
well as more distal effects of test use, is often highly
sensitive to context. Therefore, the principles noted here
relate to clarifying context factors and, to the extent
possible, using that clarity to guide study selection
(inclusion/exclusion), description, analysis, and summariza-
tion. In applying the principles described below, the PICOTS
typology can serve as a framework for assuring relevant
factors have been systematically assessed (see Table 1).
3,4
Principle 1: Identify Important Contextual Factors. In an
ideal review, all possible factors related to the impact of a
test use on health outcomes should be considered. However,
this is usually not practical, and some tractable list of factors
must be considered before initiating a detailed review.
Consider factors that could affect the causal chain of direct
relevance to the key question: for instance, in assessing the
accuracy of cardiac MRI for detecting atherosclerosis, slice
thickness is a relevant factor in assessing applicability. It is
also important to consider applicability factors that could
affect a later link in the causal chain (e.g., for lesions
identified by cardiac MRI vs. angiogram, what factors may
impact the effectiveness of treatment?).
In pursuing this principle, consider contextual issues
that are especially relevant to tests, such as patient
populations, management strategy, time effects, and secu-
lar trends:
Spectrum Effect. The severity or type of disease may effect
the accuracy of the test. For example, cardiac MRI tests
may be generally accurate at identifying cardiac anatomy
and functionality, but certain factors may affect the test
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PICOTS
element
Potential characteristics to
describe and assess
Challenges when
assessing studies
Example Potential systematic
approaches for decisions
Population ▪ Justification for lumping or
splitting key questions
▪ Source of population not
described
Education/literacy level not
reported in study of pencil-
and-paper functional status
assessment
Exclude a priori if key element
crucial to assessing intended
use case is missing Or include
but:
▪ Method of identification/selection ▪ Study population poorly
specified
– Flag missing elements in
tables/text
▪ Inclusion & exclusion criteria o
for the review
▪ Key characteristics not
reported
– Organize data within key
questions by presence/absence
of key elements
▪ Demographic characteristics of
those included in review
▪ Unclear whether test
performance varies by
population
– Include presence/absence as
parameter in meta-regression
or sensitivity analyses
▪ Prevalence of condition in
practice and in studies
– Note need for challenge to be
addressed in future research
▪ Spectrum of disease in practice
and in studies
Intervention ▪ Version of test used in practice
and in studies
Version/ instrumentation not
specified
Ultrasound machines and
training of sonographers not
described in study of fetal
nuchal translucency
assessment for detection of
aneuploidy
Exclude a priori if version critical
and not assessed Or include
but:
▪ How and by whom tests are
conducted in practice and in
studies
Training/quality control not
described
– Contact authors for clarification
▪ Cutoff/diagnostic thresholds
applied in practice and in studies
Screening and diagnostic
uses mixed
– Flag version of test or deficits
in reporting in tables/text
▪ Skill of assesors when
interpretation of test required in
studies
– Discuss implications
– Model cutoffs and conduct
sensitivity analyses
Comparator ▪ Use of gold standard vs. “alloy”
standard in studies
Gold standard not applied Cardiac CT compared with
stress treadmill without use of
angiography as a gold
standard
Exclude a priori if no gold
standard Or include but:
▪ Alternate or “usual” test used in
the studies
Correlational data only – Restrict to specified
comparators
▪ How test is used as part of
management strategy (e.g., triage,
replacement, or add-on) in
practice and in studies
– Group by comparator in tables/
text
▪ In trials is comparator no testing
vs. usual care with ad hoc testing
Outcome of use
of the test
▪ How accuracy outcomes selected
for review relate to use in
practice:
Failure to test “normals,” or
subset, with gold standard
P-value provided for mean of
continuous test results by
disease status but confidence
bounds not provided for
performance characteristics
Exclude a priori if test results
cannot be mapped to disease
status (i.e., 2 × 2 or other test
performance data cannot be
extracted) Exclude if subset of
“normals” not tested Or include
but:
▪ Accuracy of disease status
classification
Precision of estimates not
provided
– Flag deficits in tables/text
￿ Sensitivity/specificity Tests used as part of
management strategy in
which exact diagnosis is
less important than “ruling
out” a disease
– Discuss implications
￿ Predictive values – Assess heterogeneity in meta-
analysis and comment of
sources of heterogeneity in
estimates
￿ Likelihood ratios
￿ Diagnostic odds ratio
￿ Area under curve
￿ Discriminant capacity
Clinical
Outcomes
from test
results
▪ How studies addressed clinical
outcomes selected for the review:
▪ Populations and study
designs of included studies
heterogeneous with varied
findings
Bone density testing reported
in relation to fracture risk
reduction without
consideration of prior fracture
or adjustment for age
Exclude if no disease outcomes
and outcomes key to
understanding intended use
case Or include and:
￿ Earlier diagnosis ▪ Data not stratified or
adjusted for key predictors
– Document details of deficits in
tables/text
￿ Earlier intervention – Discuss implications
￿ Change in treatment given – Note need for challenge to be
addressed in future research
￿ Change in sequence of other
testing
￿ Changeinsequence/intensityofcare
￿ Improvedoutcomes, quality oflife,
costs, etc.
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obesity. Reviews must identify these factors ahead of time
and justify when to “split” questions or to conduct sub-
group analyses.
Tests as Part of a Management Strategy. Studies on cardiac
MRI often select patients with a relatively high pre-test
probability of disease (i.e., presumably pre-screened with
other non-invasive testing such as stess EKG) and evaluate
the diagnostic accuracy when compared to a gold standard
of x-ray coronary angiography. However, the test
performance under these conditions does not necessarily
apply when used in patients with lower pre-test probability
of disease, such as when screening patients with no
symptoms or when used as an initial triage test (i.e.,
compared to stress EKG) rather than an add-on test after
initial screening. It is important for reviewers to clarify and
distinguish the conditions in which the test is studied and in
which it is likely to be used.
Methods of the Test Over Time. Diagnostics, like all
technology, evolve rapidly. For example, MRI slice
thickness has fallen steadily over time, allowing resolution
of smaller lesions. Thus, excluding studies with older
technologies and presenting results of included studies by
slice thickness may both be appropriate. Similarly, antenatal
medical tests are being applied earlier and earlier in
gestation, and studies of test performance would need to
be examined by varied cutoffs for stages of gestation, and
genetic tests are evolving from detection of specific
polymorphisms to full gene sequences. Awareness of these
changes should guide review parameters such as date range
selection and eligible test type for the included literature to
help categorize findings and discussion of results.
Secular Trends in Population Risk and Disease
Prevalence. Direct and indirect changes in the secular
setting (or differences across cultures) can influence medical
test performance and applicability of related literature. As
an example, when examining the value of screening tests
for gestational diabetes, test performance is likely to be
affected by the average age of pregnant women, which has
risen by more than a decade over the past 30 years, and by
the proportion of the young female population that is obese,
which has also risen steadily. Both conditions are associated
with risk of type II diabetes. As a result, we would expect
the underlying prevalence of undiagnosed type II diabetes
in pregnancy to be increased, and the predictive values and
cost-benefit ratios of testing, and even the sensitivity and
specificity in general use, to change modestly over time.
Secular trends in population characteristics can have
indirect effects on applicability when population character-
istics change in ways that influence ability to conduct the
test. For example, obesity diminishes image quality in
tests, such as ultrasound for diagnosis of gallbladder
disease or fetal anatomic survey, and MRI for detection
Table 1. (continued)
PICOTS
element
Potential characteristics to
describe and assess
Challenges when
assessing studies
Example Potential systematic
approaches for decisions
Timing ▪ Timing of availability of results to
care team in studies and how this
might relate to practice
▪ Sequence of use of other
diagnostics unclear
D-dimer studies in which it is
unclear when results were
available relative to DVT
imaging studies
Exclude if timing/sequence is
key to understanding intended
use case Or include and:
▪ Placement of test in the sequence
of care (e.g., relationship of test
to treatment or follow-on
management strategies) of studies
and how this might relate to
practice
▪ Time from results to
treatment not reported
– Contact authors for information
▪ Timing of assessment of disease
status and outcomes in studies
▪ Order of testing varies
across subjects and was
not randomly assigned
– Flag deficits in tables/text
– Discuss implications
– Note need for challenge to be
addressed in future research
Setting ▪ How setting of test in studies
relate to key questions and
current practice:
▪ Resources available to
providers for diagnosis and
treatment of condition vary
widely
Diagnostic evaluation provided
by geriatricians in some
studies and unspecified
primary care providers in
others
Exclude if care setting known to
influence test/outcomes or if
setting is key to understanding
intended use case Or include
but:
￿ Primary care vs. specialty care ▪ Provider type/specialty
vary across settings
– Document details of setting
￿ Hospital-based ▪ Comparability of care in
international settings
unclear
– Discuss implications
￿ Routine processing vs.
specialized lab or facility
￿ Specialized personnel
￿ Screening vs. diagnostic use
**Abbreviations: CT=computed tomography; DVT=deep venous thrombosis
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tests often restrict enrollment to persons with normal body
habitus, current population trends in obesity mean that
such studies exclude an ever-increasing portion of the
population. As a result, clinical imaging experts are
concerned that these tests may not perform in practice as
described in the literature because the actual patient
population is significantly more likely to be obese than
the study populations. Expert guidance can identify such
factors to be considered.
Prevalence is inexorably tied to disease definitions that
may also change over time. Examples include: (1) criteria to
diagnose acquired immune deficiency syndrome (AIDS),
(2) the transition from cystometrically defined detrusor
instability or overactivity to the symptom complex “over-
active bladder,” and (3) the continuous refinement of
classifications of mental health conditions recorded in the
Diagnostic and Statistical Manual updates.
5 If the diag-
nostic criteria for the condition change, the literature may
not always capture such information; thus, expert knowl-
edge with a historical vantage point can be invaluable.
Routine Preventive Care over Time. Routine use of a
medical test as a screening test might be considered an
indirect factor that alters population prevalence. As lipid
testing moved into preventive care, the proportion of
individuals with cardiovascular disease available to be
diagnosed for the first time with dyslipidemia and eligible
to have the course of disease altered by that diagnosis has
changed. New vaccines, such as the human papilloma virus
(HPV) vaccine to prevent cervical cancer, are postulated to
change the distribution of viral subtypes in the population
and may influence the relative prevalence of subtypes
circulating in the population. As preventive practices
influence the natural history of disease, such as increasing
proportions of a population receiving vaccine, they also
change the utility of a medical test, like that for HPV
detection. Knowledge of preventive care trends is an
important component of understanding current practice to
consider as a backdrop when contextualizing the
applicability of a body of literature.
Treatment Trends. As therapeutics arise that change the
course of disease and modify outcomes, literature about the
impact of diagnostic tools on outcomes requires additional
interpretation. For example, the implications of testing for
carotid arterial stenosis are likely changing as treatment of
hypertension and the use of lipid-lowering agents have
improved.
We suggest two steps to ensure that data about
populations and subgroups are uniformly collected and
useful. First, refer to the PICOTS typology
3,4 (see Table 1)
to identify the range of possible factors that might affect
applicability and consider the hidden sources of limitations
noted above. Second, review the list of applicability factors
with stakeholders to ensure common vantage points and
identify any hidden factors specific to the test or history of
its development that may influence applicability. Features
judged by stakeholders to be crucial to assessing applica-
bility can then be captured, prioritized, and synthesized in
the process of designing the process and abstracting data for
an evidence review.
Principle 2: Be Prepared to Deal with Additional Factors
Affecting Applicability. Despite best efforts, some
contextual factors relevant to applicability may only be
uncovered after a substantial volume of literature has been
reviewed. For example, in a meta-analysis, it may appear
that a test is particularly inaccurate for older patients,
although age was never considered explicitly in the key
questions or in preparatory discussions with an advisory
committee. It is crucial to recognize that like any
relationship discovered a posteriori, this may reflect a
spurious association. In some cases, failing to consider a
particular factor may have been an oversight; in retrospect,
the importance of that factor on the applicability of test
results may be physiologically sensible and supported in the
published literature. Although it may be helpful to revisit
the issue with an advisory committee, when in doubt, it is
appropriate to comment on an apparent association and
clearly state that it is a hypothesis, not a finding.
Principle 3: Justify Decisions to “Split” or Restrict the
Scope of a Review. In general, it may be appropriate to
restrict a review to specific versions of the test, selected
study methods or types, or populations most likely to be
applicable to the group(s) whose care is the target of the
review such as a specific group (e.g., people with arthritis,
women, obese patients) or setting (e.g., primary care
practice, physical therapy clinics, tertiary care neonatal
intensive care units). These restrictions may be appropriate
(1) when all partners are clear that a top priority of a review
is applicability to a particular target group or setting, (2)
when there is evidence that test performance in a specific
subgroup differs from the test performance in the broader
population or setting or that a particular version of the test
performs differently than the current commonly used
version. Restriction of reviews is efficient when all
partners are clear that a top priority of a review is
applicability to a particular target group or setting.
Restriction can be more difficult to accomplish when
parties differ with respect to the value they place on less
applicable but nonetheless available evidence. Finally,
restriction is not appropriate when fully comprehensive
summaries including robust review of limitations of extant
literature are desired.
Depending on the intent of the review, restricting the
review during the planning process to include only specific
S43 Hartmann et al.: Assessing Applicability of Medical Test Studies JGIMversions of the test, selected study methods or types, or
populations most likely to be applicable to the group(s)
w h o s ec a r ei st h et a r g e to ft h er e v i e wm a yb ew a r r a n t e d .
For instance, if the goal of a review is to understand the
risks and benefits of colposcopy and cervical biopsies in
teenagers, the portion of the review that summarizes the
accuracy of cervical biopsies for detecting dysplasia might
be restricted to studies that are about teens; that present
results stratified by age; or that include teens, test for
interaction with age, and find no effect. Alternatively, the
larger literature could be reviewed with careful attention to
biologic and health systems factors that may influence
applicability to young women.
In practice, we often use a combination of inclusion
and exclusion criteria based on consensus along with
careful efforts to highlight determinants of applicability in
the synthesis and discussion. Decisions about the intended
approach to the use of literature that is not directly
applicable need to be tackled early to ensure uniformity
in review methods and efficiency of the review process.
Overall, the goal is to make consideration of applicability a
prospective process that is attended to throughout the
review and not a matter for post hoc evaluation.
Principle 4: Maintain a Transparent Process. As a
general principle, reviewers should address applicability
as they define their review methods and document their
decisions in a protocol. For example, time-varying factors
should prompt consideration of using timeframes as
criteria for inclusion or careful descriptions and analyses
as approprite of the possible impact of thes effects on
applicability.
Transparency is essential, particularly when a review
decision may be controversial. For example, after devel-
oping clear exclusion criteria based on applicability, a
reviewer may find themselves “empty-handed.” In retro-
spect, experts—even those accepting the original exclusion
criteria—may decide that some excluded evidence may
indeed be relevant by extension or analogy. In this event, it
may be appropriate to include and comment on this
material, clearly documenting how it may not be directly
applicable to key questions, but represents the limited state
of the science.
AN ILLUSTRATION
Our work on the 2002 Cervical Cancer Screening Summary
of the Evidence for the US Preventive Services Task Force
6
illustrates several challenges and principles at work: the
literature included many studies that did not use gold
standards or testing of normals, and many did not relate
cytologic results to final histopathologic status. We encoun-
tered significant examples of changes in secular trends and
availability and format of medical tests: liquid-based
cervical cytology was making rapid inroads into practice;
resources for reviewing conventional Pap smear testing
were under strain from a shortage of cytotechnologists in
the workforce and from restrictions on the volume of slides
they could read each day; several new technologies had
entered the market designed to use computer systems to
pre- or postscreen cervical cytology slides to enhance
accuracy; and the literature was beginning to include
prospective studies of adjunct use of HPV testing to
enhance accuracy or to triage which indiviudals needed
evaluation with colposcopy and biopsies to evaluate for
cervical dysplasia and cancer. No randomized controlled
trials (RCTs) were available using, comparing, or adding
new tests or technologies to prior conventional care.
Because no data were available comparing the effects
of new screening tools or strategies on cervical cancer
outcomes, the report focused on medical test character-
istics (sensitivity, specificity, predictive values, and likeli-
hood ratios), reviewing three computer technologies, two
liquid cytology approaches, and all methods of HPV
testing. Restricting the review to techologies available
in the United States, and therefore most applicable, would
have reduced the scope substantially. Including all the
technologies to determine if there were clear differences
among techniques made clear whether potentially compa-
rable or superior methods were being overlooked or no
longer offered, but may have also unnecessarily compli-
cated the findings. Only in retrospect, after the decision to
include all tests was made and the review conducted, were
we able to see that this approach did not substantially add
to understanding the findings because the tests that were
no longer available were not meaningfully superior.
Although clearly describing the dearth of information
available to inform decisions, the review was not able to
provide needed information. As a means of remediation, not
planned in advance, we used prior USPSTF meta-analysis
data on conventional Pap medical test performance
7, along
with the one included paper about liquid cytology
8,t o
illustrate the potential risk of liquid cytology overburdening
care systems with detection of low-grade dysplasia while
not substantively enhancing detection of severe disease or
cancer.
9 The projections from the report have since been
validated in prospective studies.
For two specific areas of applicability interest (younger
and older age, and hysterectomy status), we included
information about underlying incidence and prevalence in
order to provide context, as well as to inform modeling
efforts to estimate the impact of testing. These data helped
improve understanding the burden of disease in the
subgroups compared with other groups, and improve
understanding about the yield and costs of screening in
the subgroups compared with others.
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Review teams need to familiarize themselves with the
availability, technology, and contemporary clinical use of
the test they are reviewing. They should consider current
treatment modalities for the related disease condition, the
potential interplay of the disease severity and performance
characteristics of the test, and the implications of particular
study designs and sampling strategies for bias in the
findings about applicability.
As examples throughout this report highlight, applicabil-
ity of a report can be well served by restricting inclusion of
marginally related or outdated studies. Applicability is
rarely enhanced by uncritically extrapolating results from
one context to another. For example, we could not estimate
the clinical usefulness of HPV testing among older women
from trends among younger women. In the design and
scoping phase for a review, consideration of the risks and
advantages of restricting the scope or excluding publica-
tions with specific types of flaws, benefits from explicit
guidance from clinical, medical testing, and statistical
experts about applicability challenges.
Often the target of interest is intentionally large—for
example, all patients within a health system, a payer group
such as Medicare, or a care setting such as a primary care
practice. Regardless of the path taken—exhaustive or
narrow—the review team must take care to group findings
in meaningful ways. For medical tests, this means gathering
and synthesizing data in ways that enhance ability to readily
understand applicability. Grouping summaries of the find-
ings using familiar structures like PICOTS can enhance how
clearly the applicability issues are framed, for instance
grouping results by the demographics of the population
included: all women, women and men, by the intervention,
grouping together studies that used the same version of the
test, or by outcomes, grouping together those studies that
report an intermediate marker versus those that measured
the actual outcome of interest. This may mean that studies
are presented within the review more than once, grouping
findings along different “applicability axes” to provide the
clearest possible picture.
Since most systematic reviews are conducted for the
practical purpose of supporting informed decisions and
optimal care, keeping applicability in mind from start to finish
is an investment bound to pay off in the form of a more useful
review. The principles summarized in this review can assure
valuable aspects of weighing applicability are not overlooked
and that review efforts support evidence-based practice.
KEY POINTS
& Early in the review planning process, systematic reviewers
should identify important contextual factors that may
affect test performance (Table 1).
& Reviewers should carefully consider and document justifica-
tion for how these factors will be addressed in the review—
whether through restricting key questions or from careful
assessment, grouping, and description of studies in a
broader review.
○ A protocol should clearly document which populations
or contexts will be excluded from the review and how the
review will assess subgroups.
○ Reviewers should document how they will address
challenges in including studies that may only partly fit
with the key questions or inclusion/exclusion criteria,
or that poorly specify the context.
& The final systematic review should include a description of
the test’s use in usual practice and care management and
how the studies fit with the usual practice.
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